8-K: Revvity Reports Q3 2025 Results, Raises Full-Year EPS Guidance

Revvity announced third quarter 2025 financial results with $699 million revenue, 1% organic growth, mixed EPS, and raised its full-year adjusted EPS guidance.

Summary

• Third quarter 2025 revenue reached $699 million, a 2% reported increase and 1% organic growth compared to the prior year.
• GAAP earnings per share (EPS) for Q3 2025 was $0.40, down from $0.77 in Q3 2024.
• Adjusted EPS from continuing operations was $1.18, a decrease from $1.28 in Q3 2024.
• GAAP operating income from continuing operations was $82 million, with a margin of 11.7%.
• Adjusted operating income was $182 million, with an adjusted operating profit margin of 26.1%.
• The Board of Directors authorized a new two-year $1 billion share repurchase program.
• Full-year 2025 revenue guidance was updated to $2.83-$2.88 billion to reflect recent changes in foreign currency exchange rates.
• Full-year 2025 organic growth guidance was reaffirmed at 2% to 4%.
• Full-year 2025 adjusted EPS guidance was raised to a range of $4.90 to $5.00.

Sentiment

Score: 7

Explanation: While Q3 GAAP and Adjusted EPS declined year-over-year, the company reported modest revenue growth and, more importantly, raised its full-year adjusted EPS guidance and authorized a significant $1 billion share repurchase program. These forward-looking actions and improved guidance signal management's confidence and a positive outlook despite some current quarter headwinds.

Positives

• Revenue increased by 2% reported and 1% organically to $699 million in Q3 2025.
• Full-year 2025 adjusted EPS guidance was raised to $4.90-$5.00, indicating an improved outlook for profitability.
• A new two-year $1 billion share repurchase program was authorized, signaling confidence in future performance and commitment to shareholder returns.
• The Diagnostics segment showed 3% reported revenue growth and 2% organic revenue growth.
• Management expressed strong execution and positioning for greater success in 2026 and beyond.

Negatives

• GAAP EPS decreased significantly to $0.40 in Q3 2025 from $0.77 in Q3 2024.
• Adjusted EPS from continuing operations declined to $1.18 in Q3 2025 from $1.28 in Q3 2024.
• GAAP operating income from continuing operations decreased to $82 million from $98 million in the prior year.
• GAAP operating profit margin from continuing operations decreased to 11.7% from 14.3%.
• Adjusted operating income decreased to $182 million from $193 million in the prior year.
• Adjusted operating profit margin decreased to 26.1% from 28.3%.
• The Life Sciences segment organic revenue was flat (0%) in Q3 2025.

Risks

• Markets into which products are sold may decline or not grow as anticipated.
• Fluctuations in global economic and political environments, including as a result of recently implemented and threatened tariff increases.
• Failure to introduce new products in a timely manner.
• Inability to execute acquisitions and divestitures, license technologies, or successfully integrate acquired businesses or licensed technologies.
• Inability to compete effectively.
• Fluctuation in quarterly operating results and inability to adjust operations to address unexpected changes.
• Significant disruption in third-party package delivery and import/export services or significant increases in prices for those services.
• Disruptions in the supply of raw materials and supplies.
• Inability to retain key personnel.
• Significant disruption in information technology systems or cybercrime.
• Inability to realize the full value of intangible assets.
• Failure to adequately protect intellectual property.
• Loss of any licenses or licensed rights.
• The manufacture and sale of products exposing the company to product liability claims.
• Failure to maintain compliance with applicable government regulations, data privacy, and information security laws and regulations.
• Regulatory changes, including healthcare industry regulations.
• Economic, political, and other risks associated with foreign operations.
• Inability to obtain future financing.
• Restrictions in credit agreements.
• Significant fluctuations in stock price.
• Reduction or elimination of dividends on common stock.

Future Outlook

Revvity updated its full-year 2025 revenue guidance to $2.83-$2.88 billion, primarily reflecting recent foreign currency exchange rate changes, while reaffirming organic growth guidance of 2% to 4%. The company also raised its full-year adjusted EPS guidance to a range of $4.90 to $5.00, indicating an improved profitability outlook. Management anticipates strong execution to position the company for greater success in 2026 and beyond.

Management Comments

• Prahlad Singh, president and chief executive officer, stated, 'We performed well during the third quarter as a number of key innovations and strategic partnerships have begun to come to fruition. Our strong level of execution is positioning the Company for even greater success in 2026 and beyond.'

Industry Context

Revvity operates in the health science solutions sector, providing technologies and services across pharmaceutical, biotech, diagnostic labs, academia, and government. The modest organic growth of 1% overall, with flat growth in Life Sciences and 2% in Diagnostics, suggests a stable but not rapidly expanding market for its core offerings. The company's focus on innovation and strategic partnerships aligns with broader industry trends towards advanced multi-omics technologies, biomarker identification, and digital health solutions.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential benefit from share repurchases increasing EPS and supporting stock price, and continued dividends.
• Employees: Risk of restructuring charges and the importance of retaining key personnel are noted.
• Customers: Continued focus on innovation and strategic partnerships aims to deliver advanced health science solutions.

Next Steps

• The company will discuss its third quarter 2025 results and business outlook during a webcast on October 27, 2025, at 8:00 a.m. Eastern Time.

Key Dates

Recommendation

Despite a year-over-year decline in Q3 GAAP and Adjusted EPS, Revvity's decision to raise its full-year adjusted EPS guidance and authorize a substantial $1 billion share repurchase program are strong indicators of management's confidence in future profitability and commitment to shareholder value. The modest organic revenue growth, particularly in Diagnostics, suggests underlying business stability. The share repurchase program is a proactive capital allocation strategy that can enhance shareholder returns and signal undervaluation. These forward-looking positive signals outweigh the mixed current quarter performance, making the stock an attractive investment.

Keywords

Revvity, RVTY, Financial Results, Earnings, Q3 2025, Life Sciences, Diagnostics, Share Repurchase, EPS Guidance, Revenue Growth, Biotech, Healthcare Solutions, SEC Filing